Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advanced Cefazolin Prophylaxis During Coronary Artery Bypass Grafting
2013-000998-68Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2013
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cefazolin in coronary arteriosclerosis and surgical site infection (SSI), sponsored by Medical University of Vienna. Primary endpoint: Baseline subcutaneous cefazolin concentrations in surgically affected tissue. Started May 2013; status: completed.
02
Drugs
cefazolin
03
Conditions
coronary arteriosclerosissurgical site infection (SSI)
Beyond the preview
Go deeper on 2013-000998-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000998-68.